Article
Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer.
Nature - 13 Jul 2017
Sahin Ugur, Derhovanessian Evelyna, Miller Matthias, Kloke Björn-Philipp, Simon Petra, Löwer Martin, Bukur Valesca, Tadmor Arbel D, Luxemburger Ulrich, Schrörs Barbara, Omokoko Tana, Vormehr Mathias, Albrecht Christian, Paruzynski Anna, Kuhn Andreas N, Buck Janina, Heesch Sandra, Schreeb Katharina H, Müller Felicitas, Ortseifer Inga, Vogler Isabel, Godehardt Eva, Attig Sebastian, Rae Richard, Breitkreuz Andrea, Tolliver Claudia, Suchan Martin, Martic Goran, Hohberger Alexander, Sorn Patrick, Diekmann Jan, Ciesla Janko, Waksmann Olga, Brück Alexandra-Kemmer, Witt Meike, Zillgen Martina, Rothermel Andree, Kasemann Barbara, Langer David, Bolte Stefanie, Diken Mustafa, Kreiter Sebastian, Nemecek Romina, Gebhardt Christoffer, Grabbe Stephan, Höller Christoph, Utikal Jochen, Huber Christoph, Loquai Carmen, Türeci Özlem
Abstract excerpt
T cells directed against mutant neo-epitopes drive cancer immunity. However, spontaneous immune recognition of mutations is inefficient. We recently introduced the concept of individualized mutanome vaccines and implemented an RNA-based poly-neo-epitope approach to mobilize immunity against a spectrum of cancer mutations. Here we report the first-in-human application of this concept in melanoma. We set up a...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.